Key facts
- This page summarizes Erik Harris's Form 4 filing for Denali Therapeutics Inc. (DNLI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2024, 18:27.
Erik Harris - 31 May 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)
- Reporting relationship
- Director
- Issuer ticker
- DNLI
- Reported as of
- 31 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 18:27:58 UTC
- Prior SEC filing
- 05 Mar 2024
- Next SEC filing
- 07 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tyler Nielsen, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Erik Harris filed Form 4 for Denali Therapeutics Inc. (DNLI) on 04 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,967
- Change %
- +54%
- Price
- $0.000000
- Shares after
- 17,052
- Date
- 31 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNLI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +17,901
- Change %
- Price
- $0.000000
- Shares after
- 17,901
- Date
- 31 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,901
- Exercise price
- $18.56
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Footnote F2
Includes 9,402 unvested RSUs.
Footnote F3
100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.